Biodiversity: To Protect Ourselves, We Must Safeguard Our Planet

Business, Women, Youth, and Other Stakeholders

“80% of registered medicines come from our biodiversity of plants or have been inspired by natural products. Right now, the cure for cancer, or COVID, is going extinct” — Peter Bickerton, Earlham Institute

The COVID-19 pandemic has shown how vital biodiversity is. It acts as a protection against new diseases. It is also an essential part of the medical response. If we fail to safeguard healthy, intact ecosystems, not only will the world experience more pandemic events.  Moreover, we will also have fewer pharmaceutical development options.

biodiversity. Flat-style digital illustration featuring the message “TO PROTECT OURSELVES, WE MUST SAFEGUARD OUR PLANET” above a stylized Earth surrounded by wildlife, including a fox, elephant, turtle, monkey, egret, butterfly, sunflower, and green foliage.Protecting biodiversity means protecting ourselves. Safeguarding the planet ensures a safer, healthier future for all life on Earth.

The relationship between nature and health has been at the forefront of the COVID-19 pandemic, including vaccine development. Despite growing recognition of the importance of biodiversity, it continues to decline. This decline has significant consequences for human health. It also impacts the pharmaceutical industry. Research suggests that we will be losing an ‘important drug every two years.’

Biodiversity and the Pharmaceutical Industry

The State of Knowledge Review on biodiversity and health by CBD, WHO, and UNEP wrote an report. It estimates: “The value of the global trade in plants used for medicinal purposes will exceed US$ 2.5 billion. This trade is increasingly driven by industry demand.” Research conducted by Erwin, López-Legentil, and Schuhmann suggests significant findings. In the marine environment, an estimated $563 billion in cancer medicines await discovery. This potential value will also extend up to $5.69 trillion.

In an interview with Mongabay, André Hoffmann is a board member of Swiss pharmaceutical company Roche. He outlines the importance of nature for the industry. He highlights the shifting attitudes towards sustainability. There is increasing pressure from customers, employees, and investors.

How Are Pharmaceutical Companies Responding?

Pharmaceutical industry actors increasingly recognize the importance of biodiversity conservation for their long-term prospects. In the CBD policy brief Bioscience at a Crossroads, Sarah A. Laird emphasizes the increasing support for the Nagoya Protocol on Access and Benefit-sharing:

“Large pharmaceutical companies support the need to sign agreements, reach mutually agreed terms, and share benefits. Benefit-sharing packages that include a wide range of monetary and non-monetary benefits over time have become standard practice.”

This shift is also represented at the company level, with many devising and implementing corporate strategies for biodiversity. Bayer, for example, has articulated a strategy. It includes protecting forests. The strategy also supports farmers in integrating biodiversity conservation and climate adaptation into crop production.

The industry, though, must continue to improve biodiversity supports and practices, including quantifying impacts, as Hoffman highlights:

“We need to find a way to measure the impact that businesses are having on this dimension. Additionally, we need to assess the impact that biodiversity loss has on business.”

How Can the Pharmaceutical Industry Be Part of the Solution for Nature?

  1. Recognize that investing in biodiversity is good for the bottom line.
  2. Engage with indigenous communities to preserve traditional knowledge on medicinal uses of plant and animal species.
  3. Implement the Nagoya Protocol to guarantee the fair sharing of benefits from drug discoveries.
  4. Mainstream biodiversity within the pharmaceutical industry, incorporating skills, environmental analysis, and risk assessment.
  5. Promote sustainability in the commercialization of natural products.

Biodiversity supports human well-being in countless ways. The pharmaceutical industry shows one of the most tangible examples. If we hope to continue to improve human health, we must safeguard our biodiversity. We need to advance medical discoveries and respond quickly to emerging health risks. It’s essential to support sustainable use of biodiversity. We also need to make sure that the benefits from biomedical discovery are shared by all.

Sources: June 2021

Comments are closed.

Up ↑